Close Menu

NEW YORK – Abbott Laboratories announced Monday its SARS-CoV-2 IgM antibody test has received Emergency Use Authorization from the US Food and Drug Administration.

The AdviseDx SARS-CoV-2 IgM serology test is for use on the firm's Architect and Alinity platforms. The test has shown nearly 100 percent specificity and 95 percent sensitivity in patients 15 days after symptom onset, the company said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.